NCT04610359

Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis

Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis; Open-labelled, Single Center, Phase 1 Study

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 3 (estimated)
• Sponsor: Asan Medical Center · Academic / Other
• Sex: Female
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

This study primarily aimed to evaluate the safety of human embryonic stem cell (hESC)-derived mesenchyma stem cells in interstitial cystitis.

Conditions

• Interstitial Cystitis
• Stem Cell Transplant
• Mesenchymal Stem Cell

Interventions

Type	Name	Description
DRUG	MR-MC-01	Submucosal injection of 2.0 x 10,000,000/5ml (1mL \* 5 sites)

Timeline

• Start date: 2020-10-20
• Primary completion: 2022-10-01
• Completion: 2022-12-01
• First posted: 2020-10-30
• Last updated: 2020-10-30

Locations

1 site across 1 country: South Korea